SCHEMBL29784651

SCHEMBL29784651

COc1cc(F)cc(CNC(=O)OC(C)(C)C)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.43
GRM2 Q14416 1/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
GFER P55789 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TACR1 P25103 1/20 0.41
EPAS1 Q99814 1/20 0.41
KDM4A O75164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GAA P10253 1/20 0.39
CYP4F2 P78329 1/20 0.39
CYP4A11 Q02928 1/20 0.39
NAMPT P43490 1/20 0.39
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
ADORA2A P29274 1/20 0.38
ADORA2B P29275 1/20 0.38
WDR5 P61964 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12791343 0.88 GRM2 (0.46) GRM2L3MBTL1KDM4AGAANAMPT
SCHEMBL23684240 0.86 CNR1 (0.43) SMN1; SMN2GAANAMPT
SCHEMBL3507902 0.83 DYRK1A (0.43) DYRK1AL3MBTL1GFERHSD17B10TACR1
SCHEMBL7999651 0.83 DYRK1A (0.43) DYRK1AL3MBTL1GFERHSD17B10TACR1
SCHEMBL8009967 0.83 GRM2 (0.43) GRM2L3MBTL1EPAS1KDM4AGAA
SCHEMBL16020324 0.83 GRM2 (0.43) GRM2L3MBTL1EPAS1KDM4AGAA
SCHEMBL4973592 0.83 L3MBTL1 (0.44) GRM2L3MBTL1EPAS1KDM4AGAA
SCHEMBL3877931 0.82 GRM2 (0.41) GRM2L3MBTL1KDM4ASMN1; SMN2GAA
SCHEMBL22363679 0.82 EPAS1 (0.48) GRM2L3MBTL1EPAS1KDM4AGAA
SCHEMBL8014788 0.82 GRM2 (0.43) GRM2L3MBTL1EPAS1KDM4AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174616-A1 HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2024-05-30 US disclosed
WO-2022169985-A1 HDAC6 INHIBITORS AND USES THEREOF EIKONIZO THERAPEUTICS, INC. (US) 2022-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174616-A1 HDAC6 INHIBITORS AND USES THEREOF HDAC6, HDAC1, HDAC5 DYRK1A 3975/4885GRM2 831/4885L3MBTL1 2238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.